33 results
8-K
EX-99.1
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
safety signals for izokibep were observed. The most common adverse events were mild-to-moderate injection site reactions, headache, nasopharyngitis … , without their associated safety liabilities. Izokibep is currently being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis
8-K
EX-10.1
SLRN
Acelyrin, Inc.
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing
8-K
EX-99.1
SLRN
Acelyrin, Inc.
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
evidence of the associated safety liabilities.
The Phase 2b/3 clinical trial is expected to be registration-enabling and the dose selection of 160mg every
8-K
EX-10.1
6phl6g6a8b m7r
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.2
kim411
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
DEF 14A
02ud lu0c8ozax
22 Apr 24
Definitive proxy
4:10pm
10-K
mfposs7dj 37
28 Mar 24
Annual report
4:21pm
8-K
EX-99.1
4z5er uuc8yssxi5
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
EX-99.2
qpus tpsgi
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.3
j2qutqiqjprzntlx
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
z7be35ppj
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
osfq0xojq8dhddak
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
gwqgwj qk
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
EX-99
vjmgmnl
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
EX-99.1
4iq7uh542m2xp
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
EX-99.1
mkcp 16bxir6
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm